FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine. What is described is the use of magnesium stearate in an inhalation powder formulation containing carrier particles to inhibit or reduce chemical degradation of the active ingredient containing a hydrolysis-sensitive group. The active ingredient is specified in classes consisting of antimuscarinics, phosphodiesterase-4 inhibitors and steroids.
EFFECT: in presence of magnesium stearate, the active ingredients have higher chemical storage-stability, particularly at high temperatures and/or high percentage of moisture.
7 cl, 2 dwg, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF PRODUCING PYRROLIDINIUM SALTS | 2010 |
|
RU2554878C2 |
| TREATING CONDITIONS ASSOCIATED WITH HYPERINSULINEMIA | 2015 |
|
RU2722179C2 |
| COMPOUNDS FOR TREATING PERIPHERAL NEUROPATHIES | 2009 |
|
RU2523281C2 |
| PHARMACEUTICAL DRUG FORMS CONTAINING LOW-DOSAGE ACTIVE COMPONENT FOR DRY POWDER INHALATORS | 2005 |
|
RU2371171C2 |
| NONPEPTIDE ANTAGONISTS OF TACHIKININ RECEPTORS | 1994 |
|
RU2140921C1 |
| HIMBACINE "НОР СЕКОПРОИЗВОДНЫЕ" WITH INHIBITORY ACTION WITH RESPECT TO THROMBIN RECEPTORS | 2004 |
|
RU2367660C9 |
| DERIVATIVES OF N-SULFONYLCARBOXYLIC ACID AMIDE INCLUDING N-CONTAINING 6-MEMBERED AROMATIC RING, FUNGICIDE AND HERBICIDE COMPOSITION AND METHODS OF STRUGGLE AGAINST WEEDS AND PATHOGENIC FUNGI | 1993 |
|
RU2117662C1 |
| NEW BICYCLIC PYRAZOLE DERIVATIVES | 2018 |
|
RU2781426C2 |
| ANTIPLATELET AND ANTIATHEROGENIC PHARMACEUTICAL COMPOSITION CONTAINING THIENEPYRIDINE DERIVATIVE AND INHIBITOR OF HMG-COA-REDUCTASE | 1997 |
|
RU2176504C2 |
| SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | 2014 |
|
RU2683793C2 |
